CCTG

OVC.1

NCT02446600

OVC.1

A Phase III Study Comparing Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

2nd+

Line of Therapy

Disease Stage.png

Relapsed / Recurrent / Refractory

Disease Stage

Target.png

Biomarker(s)

BRCA1/2

Investigational

Product

Olaparib + Cediranib Maleate

Treatment Arms

o Active Comparator: Arm I (platinum-based chemotherapy)

o Experimental: Arm II (olaparib)

o Experimental: Arm III (olaparib, cediranib maleate)